VERAPAMIL HYDROCHLORIDE | A071881 | HERITAGE PHARMACEUTICALS INC DBA AVET PHARMACEUTICALS INC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from Camargo Pharmaceutical Services, LLC on behalf of Cente... FDA-2020-P-2245 · 10 docket documents Camargo Pharmaceutical Services, LLC, on behalf of Center Laboratories, Inc., filed this citizen petition requesting that the FDA determine that the discontinued formulations of CALAN (verapamil hydrochloride) 40, 80, 120, and 160 mg oral tablets under NDA 018817 from Pfizer Inc were not discontinue | 505(q) | 2020-12-01 | Granted | Center Laboratories, Inc. |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$0.1184
per ea
Lowest NADAC/Unit
$0.0858
per ea
Brand NDCs
0
Generic NDCs
6
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 62135074390VERAPAMIL 40 MG TABLET | $0.1184 | EA | Generic | — | 2026-06-17 |
| 23155005901VERAPAMIL 40 MG TABLET | $0.1184 | EA | Generic | — | 2026-06-17 |
| 62135074490VERAPAMIL 80 MG TABLET | $0.0861 | EA | Generic | — | 2026-06-17 |
| 23155002601VERAPAMIL 80 MG TABLET | $0.0861 | EA | Generic | — | 2026-06-17 |
| 23155048601VERAPAMIL 120 MG TABLET | $0.0858 | EA | Generic | — | 2026-06-17 |
| 62135074590VERAPAMIL 120 MG TABLET | $0.0858 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.